Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look at the charts people...
...this is following a textbook bullish trend. It's normal and healthy movement and it's very exciting.
Congrats to the short term holders who have made some money and congrats to the longs on higher highs and lower lows.
There's really nothing anyone, short or long, should be upset about. This stock is behaving beautifully on large volume.
Look at the chart.
http://stockcharts.com/h-sc/ui?s=gnta
Dude, don't mislead people like that...
...and certainly don't circle your calendar. That date has little to no expected meaning for Genta. Sure' they're presenting at the largest Biotech investors conference on the planet, but it really doesn't have much to do with Genasense approval. If anything, there might be positive news about financing, but little more (maybe an update on the Agenda Phase III trial).
What people should be focused on is the Agenda Phase III trial and the awesome results that it is producing. What we also need to think about is why the FDA has turned down such a great and needed product like Genasense. It has proven results and efficacy in double blind, placebo based studies conducted around the world.
This is coming from someone who has been in this stock since .0022. I've done my DD and have to laugh at some of the posts here. Genta will realize it's market value without all the hype. They have proven, groundbreaking drugs in their pipeline and one on the market.
If they by some chance don't make it on their own, one of the larger Pharma's is going to scoop them up as the acquisition dominoes continue to fall (first one kicked over by Pfizer).
Bottom line? Don't expect huge news about FDA approval at the investors conference on the 9th, but do expect some great news from the FDA some time this quarter or 2nd quarter 2009.
The Agenda Phase III trial is expected to be fully enrolled shortly and I expect the results will continue to roll in.
If you're in now for under a penny, my advice would be to say your blessings and hang on to those shares tight. The potential here for an anticancer drug like Genasense simply can't be overstated.
Best of luck to everyone.
Is this a joke?
...I just got back to my desk and realized I've lost over 70% of my initial investment and now I can't get out. Awesome.
So much for the promises from a few.
I have to go take a shower.
Here it goes
I agree, this cheerleading is...
...getting out of control. Like I said, I've been in this since .0022 and have no plans of getting out.
Genta's pipeline of drugs are what have brought this stock back from being naked shorted into the ground.
The incessant cheerleading isn't needed and is likely to turn people off of the stock.
Let it thrive on it's own laurels as hit has since early December. Educated people can see what the company has to offer and know that it's undervalued.
In the meantime, enjoy the ride back up. It's a fun one, and I speak from experience.
I've been here since .0022
I can absolutely "feel" the cup and handles happening. It used to scare me, but now I like the feeling. Love it.
Just another cup and handle forming this morning!
Gotta love this, it's TEXTBOOK.
Don't fall for the shake...
...those that have done the DD on this company will not be shaken loose by people who have shorted this stock illegally into the ground.
Genasense has been a "Fast Track" status drug since 2005, so the FDA clearly sees the need for an antisense technology.
BERKELEY HEIGHTS, N.J., June 30, 2005 -- Genta Incorporated today announced that the Company has initiated submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking marketing approval of Genasense (oblimersen sodium) Injection, its lead anticancer compound. The NDA seeks accelerated approval for the use of Genasense in combination with fludarabine plus cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia (CLL) who have previously received fludarabine. Genasense has received Fast Track designation by FDA in CLL, meaning that the indication represents an unmet medical need. Fast Track designation enables the Company to submit the NDA on a "rolling" basis as specific sections are completed. Genta has submitted the initial section, and the Company anticipates that the NDA will be completed within 6 months. Genasense has also received designation as an Orphan Drug in CLL, which provides for a period of marketing exclusivity, certain tax benefits, and exemption from certain fees at the time of NDA submission. Accelerated approval will require the Company to conduct a confirmatory study, and Genta plans to discuss the design of that study with FDA.
http://www.drugs.com/nda/genasense_050630.html
That was a healthy pull back...
...time to make the next leg up.
Genta to present at 2009 BIO CEO Investors Conference
GNTA was given a slot today to present at BIO CEO 2009 on
Feb 9th 10AM.
http://www.ceo.bio.org/opencms/ceo/2009/companyInfo/PresentingCompanies.html
Shorts and Naked shorts...
...are screwed on GNTA.
This is what I like to call a short squeeze.
My God, huge buys going off at the ask of .0083
Thanks, Glassy!
Nice steady climb.
8's are coming
Shorters have to get out
I'm fine with it going under the radar a bit.
People are securing their position for...
...the pending FDA announcement. It's my opinion that this stock will continue to climb steadily until the FDA news comes.
If heavy buying begins after the meeting on February 9th, you could really see this stock jump.
Approval means prior levels @ ~.20
Nite on the bid at .0069
Hill is on the ask @ .007
Mr. Bigz, can you take a look at GNTA?
Wow, I'm holding a few thousand @ $8.00
...maybe I'll get back in the green before the opening bell! This is outstanding. I was expecting this to be at least until Q4 before I saw a ROI and was in it for the long run.
Great movement this morning!
The 11% decrease in short interest since December...
...tells me that people are beginning to rethink the direction of where this stock is headed.
We're headed back up.
What does it all mean, nutriman? It's actually a month over month decrease in short interest.
Short Interest
Short interest is the total number of shares of a particular stock that have been sold short by investors but have not yet been covered or closed out. This can be expressed as a number or as a percentage.
When expressed as a percentage short interest is the number of shorted shares divided by the number of shares outstanding. For example, a stock with 1.5 million shares sold short and 10 million shares outstanding has a short interest of 15% (1.5 million/10 million = 15%).
Most stock exchanges track the short interest in each stock and issue reports at month's end. These reports are great because, by showing what short sellers are doing, they allow investors to gauge overall market sentiment surrounding a particular stock. Or alternatively most exchanges provide an online tool to calculate short interest for a particular security. For example check out the Nasdaq's short interest calculator; it's very easy to use.
Reading Short Interest
A large increase or decrease in a stock's short interest from the previous month can be a very telling indicator of investor sentiment. Let's say that Microsoft's (MSFT) short interest increased by 10% in one month. This means that there was a 10% increase in the amount of people who believe the stock will decrease. Such a significant shift provides good cause for us to find out more. We would need to check the current research and any recent news reports to see what is happening with the company and why more investors are selling its stock.
A high short-interest stock should be approached for buying with extreme caution but not necessarily avoided at all cost. Short sellers (like all investors) aren't perfect and have been known to be wrong from time to time.
In fact, many contrarian investors use short interest as a tool to determine the direction of the market. The rationale is that if everyone is selling, then the stock is already at its low and can only move up. Thus, contrarians feel that a high short-interest ratio (which we will discuss below) is bullish - because eventually there will be significant upward pressure on the stock's price as short sellers cover their short positions (i.e. buy back the stocks they borrowed to return to the lender).
Short-Interest Ratio
The short-interest ratio is the number of shares sold short (short interest) divided by average daily volume. This is often called the "days-to-cover ratio" because it tells, given the stock's average trading volume, how many days it will take short sellers to cover their positions if positive news about the company lifts the price.
Again, let's assume Microsoft has a short interest of 75 million shares, while the average daily volume of shares traded is 70 million. Doing a quick and easy calculation (75,000,000/70,000,000) we find that it would take 1.07 days for all of the short sellers to cover their positions. The higher the ratio, the longer it will take to buy back the borrowed shares - an important factor upon which traders or investors decide whether to take a short position. Typically, if the days to cover stretch past eight or more days, covering a short position could prove difficult.
The NYSE Short-Interest Ratio
The NYSE short-interest ratio is another great metric used to determine the sentiment of the overall market. The NYSE short-interest ratio is the same as short interest except it is calculated as monthly short interest on the entire exchange divided by the average daily volume of the NYSE for the last month.
For example, say there are five billion shares sold short in August and the average daily volume on the NYSE for the same period is one billion shares per day. This gives us a NYSE short-interest ratio of five (five billion /one billion). This means that, on average, it will take five days to cover the entire short position on the NYSE. In theory a higher NYSE short-interest ratio indicates a more bearish sentiment towards the exchange.
Short Squeeze
Some bullish investors see a high short interest as an opportunity. This outlook is based on the short-interest theory. The rationale is, if you are short selling a stock and the stock keeps rising rather than falling, you'll most likely want to get out before you lose your shirt. A short squeeze occurs when short sellers are scrambling to replace their borrowed stock thereby increasing demand and decreasing supply, forcing prices up. Short squeezes tend to occur more often in smaller cap stocks, which have a very small float (supply), but large caps are certainly not immune from this situation.
If a stock has a high short interest, short positions may be forced to liquidate and cover their position by purchasing the stock. If a short squeeze occurs and enough short sellers buy back the stock, the price could go even higher. Unfortunately, however, this is a very difficult phenomenon to predict.
Conclusion
Although it can be a telling indicator, an investment decision should not be based entirely on a stock's short interest; however, investors often overlook this ratio despite its widespread availability. Unlike the fundamentals of a company, the short interest requires little or no calculations. Half a minute of time to look up short interest can help provide valuable insight into what sentiment investors have towards a particular company or exchange.
Bollinger pinch!
That is NO stretch...
...from 3:30pm this afternoon until 3:32, we've moved up from .0064 to .0067 with huge buys going off at the ask. We have 30 minutes left in the trading day with great bid support.
.007 isn't out of the question with the bids going in now.
Over 600k just went through at the ask of .0067
Hang on!
We're gonna close above 7...great support!
Here comes the run!
Getting some MOMO!!
Well, that brings the pps down, so you do the math genius.
Good for you, I think you'll be very happy with your choice. Remember to buy at the ask if you want to make money.
If it's additional confirmatory data....
...the FDA wanted, then they certainly have it at this point.
Also, the Big Pharma....
...acquisition dominoes are starting to fall. The first big one was kicked over yesterday by Pfizer.
They needed more confirmatory data...
...if you look at the latest updates from the AGENDA Phase III trial, you'll see that there is significant confirmatory and efficacy data within.
Target is 1Q2009, but can come at any time.
A lot of companies, not just shareholders...
...have a lot riding on Genasense getting approved.
People are lowballing the ask price...
...that's very annoying.
Buy at the ASK you idiots.
The AGENDA Phase 3
...intermediate results were outstanding on the double blind, world wide, trial. I really don't see how the FDA can not approve Genasense this time around.
mobiclear Issues Letter to Shareholders Updating Progress 01/27 08:58 AM
MANILA, Philippines and LAGUNA HILLS, Calif., Jan. 27 /PRNewswire-FirstCall/ -- mobiclear Inc. (MOBI:$0.01,00$0.00,000.00%) , (http://www.mobiclear.com), today issued the following letter to its shareholders:
As we leave the hectic year of 2008, and look forward to an improving worldwide economic picture in 2009, it is good to take a look at where we are, and the direction in which we are headed.
mobiclear starts 2009 much different than how it began 2008. A new CEO, COO, CFO and other management changes, including the important addition of the Chief Information Officer (CIO), have brought a new, fresh, positive look to the business.
We have undertaken an aggressive program to strengthen and enhance the scalability of the mobiclear personal identification verification technology. This technology is being branded under the name PIVOT, to emphasize that it provides "Personal Identification Verification On - Time." The enhanced technology is intended for use in relatively small local functions as well as major, international applications. PIVOT significantly enhances the security of transactions since it provides "out of channel authentication," or "ooca," otherwise known as "out of band authentication," or "ooba" using two independent communication channels. OOCA/OOBA is more secure than the traditional "two factor authentication" using a simple token, that still traverses the single channel of the Personal computer.
In addition to the PIVOT product, we are excited about developments in the integration of Voice over Internet Protocol (VoIP) to the PIVOT system. This offers cost and reliability benefits over the traditional public telephone distribution system. VoIP provides more timely connection and transaction message delivery than SMS based systems. We have made appreciable progress with providers to ensure reliable and cost effective service levels. We continue to work with providers to strengthen this method.
The global financial system crisis has caused some potential clients to focus on loss prevention and mitigation. This provides mobiclear with enhanced opportunities, since clients are seeking to provide more security to on-line banking, credit/debit card transactions and other electronic funds transfers. Our recent discussions with potential clients have shown strong interest in the PIVOT system. We are currently meeting with a number of clients, who are very interested in integrating PIVOT with their current hardware/software, and moving toward the signing of agreements for further project development and implementation.
To help secure client systems, mobiclear is developing additional security appliances based on the products acquired from Bastion Payment Systems. These leading edge appliances will be ready for testing in the second quarter of 2009 and include a firewall that will reduce risks of database and network compromise by acting as a barrier to "infections" and breaches from outside sources and an "anti-DDOS system," that reduces risks of distributed denial of service attacks, which can cripple or destroy on-line businesses.
Overall, the future looks bright. The PIVOT, combined with the firewall, and anti-DDOS appliances, will result in a much more robust product line, and we expect that commercial installation should be available in Q2 2009. The Company structure remains strong. It should be a good year, and a good future. We want to thank those shareholders who have stayed with mobiclear and we look forward to introducing the Company to a new group of stakeholders in 2009.
Sincerely,
Stephen P. Cutler
CEO
Today was the most buying that's taken place since January 8th when Genta issued 2 U.S. patents for its gallium products franchise. The interesting part is that no news went out today.
I think some prior investors who made money on the last run up to .009 a couple weeks back are getting back in the game for the pending FDA ruling.
Could get interesting.